EVOLUS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
EVOLUS, INC. (EOLS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $5.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- EVOLUS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $5.64M, a 24.63% increase year-over-year.
- EVOLUS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $5.12M, a 14.16% decline year-over-year.
- EVOLUS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $5.15M, a 1.83% decline year-over-year.
- EVOLUS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $4.52M, a 21.96% decline year-over-year.
- EVOLUS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $20.80M, a 6.55% decline from fiscal 2024.
- EVOLUS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $22.25M, a 35.22% increase from fiscal 2023.
- EVOLUS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $16.46M, a 51.92% increase from fiscal 2022.
- EVOLUS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $10.83M, a 12.40% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.64M 10-Q · filed 2026-08-05 | $10.76M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $5.12M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $20.80M 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $5.15M 10-Q · filed 2025-11-05 | $9.67M derived: sum of 2 quarters · filed 2026-08-05 | $15.64M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $4.52M 10-Q · filed 2026-08-05 | $10.49M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $5.97M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $22.25M 10-K · filed 2026-03-03 | |||
| 2024-09-30 | $5.25M 10-Q · filed 2025-11-05 | $11.04M derived: sum of 2 quarters · filed 2025-11-05 | $16.13M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | $5.80M 10-Q · filed 2025-11-05 | $10.89M derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | $5.09M 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $16.46M 10-K · filed 2026-03-03 | |||
| 2023-09-30 | $4.60M 10-Q · filed 2024-11-06 | $8.77M derived: sum of 2 quarters · filed 2024-11-06 | $12.06M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $4.17M 10-Q · filed 2024-11-06 | $7.46M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $3.29M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $10.83M 10-K · filed 2025-03-04 | |||
| 2022-09-30 | $2.48M 10-Q · filed 2023-11-07 | $5.46M derived: sum of 2 quarters · filed 2023-11-07 | $8.42M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $2.98M 10-Q · filed 2023-11-07 | $5.94M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $2.96M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $9.64M 10-K · filed 2023-03-08 | |||
| 2021-09-30 | $2.50M 10-Q · filed 2022-11-08 | $5.38M derived: sum of 2 quarters · filed 2022-11-08 | $6.99M derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | $2.89M 10-Q · filed 2022-11-08 | $4.49M derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $1.61M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $10.60M 10-K · filed 2022-03-03 | |||
| 2020-09-30 | $2.97M 10-Q · filed 2021-11-02 | $5.29M derived: sum of 2 quarters · filed 2021-11-02 | $7.96M derived: sum of 3 quarters · filed 2021-11-02 | |
| 2020-06-30 | $2.33M 10-Q · filed 2021-11-02 | $4.99M derived: sum of 2 quarters · filed 2021-11-02 | ||
| 2020-03-31 | $2.67M 10-Q · filed 2021-11-02 | |||
| 2019-12-31 | $9.62M 10-K · filed 2021-03-25 | |||
| 2019-09-30 | $2.56M 10-Q · filed 2020-10-29 | $5.04M derived: sum of 2 quarters · filed 2020-10-29 | $7.06M derived: sum of 3 quarters · filed 2020-10-29 | |
| 2019-06-30 | $2.49M 10-Q · filed 2020-10-29 | $4.50M derived: sum of 2 quarters · filed 2020-10-29 | ||
| 2019-03-31 | $2.02M 10-Q · filed 2020-10-29 | |||
| 2018-12-31 | $6.97M 10-K · filed 2020-02-25 | |||
| 2018-09-30 | $1.48M 10-Q · filed 2019-11-04 | $4.11M derived: sum of 2 quarters · filed 2019-11-04 | $5.11M derived: sum of 3 quarters · filed 2019-11-04 | |
| 2018-06-30 | $2.62M 10-Q · filed 2019-11-04 | $3.63M derived: sum of 2 quarters · filed 2019-11-04 | ||
| 2018-03-31 | $1.01M 10-Q · filed 2019-11-04 | |||
| 2017-12-31 | $586.00K 10-K · filed 2019-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |